Brensocatib
Brand names: Brinsupri ยท Active ingredient: Brensocatib
In short: BRINSUPRI is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age and older.
What is Brensocatib used for?
BRINSUPRI is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age and older.
Brensocatib dosage
The recommended dosage of BRINSUPRI is as follows:
10 mg orally once daily with or without foodor
25 mg orally once daily with or without food
Missed Dose(s)
Patients who miss a dose should take the next dose at their regular time the next day. Do not double the dose to make up for the missed dose.
How to take Brensocatib โ instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Dermatologic Adverse Reactions
Inform patients that BRINSUPRI is associated with a risk of adverse skin reactions including rash, dry skin, and hyperkeratosis. Advise patients to monitor their skin and report any new rash or skin condition .
Gingival and Periodontal Adverse Reactions
Inform patients that BRINSUPRI is associated with a risk of gingival and periodontal adverse reactions. Advise patients to have regular dental checkups while taking BRINSUPRI. Advise patients to perform routine dental hygiene .
Live Attenuated Vaccines
Instruct patients to inform the healthcare provider that they are taking BRINSUPRI prior to a potential vaccination .
Warnings & precautions
Do not take this medicine if: None.
Treatment with BRINSUPRI is associated with an increase in dermatologic adverse reactions, including rash, dry skin, and hyperkeratosis . Monitor patients for development of new rashes or skin conditions and refer patients to a dermatologist for evaluation of new dermatologic findings.
Treatment with BRINSUPRI is associated with an increase in gingival and periodontal adverse reactions . Refer patients to dental care services for regular dental checkups while taking BRINSUPRI. Advise patients to perform routine dental hygiene.
The concomitant use of BRINSUPRI and live attenuated vaccines has not been evaluated. It is unknown whether administration of live attenuated vaccines during BRINSUPRI treatment will affect the safety or effectiveness of these vaccines. The use of live attenuated vaccines should be avoided in patients receiving BRINSUPRI.
Brensocatib side effects
The following adverse reactions are described elsewhere in the labeling:
Dermatologic Adverse Reactions
Gingival and Periodontal Adverse Reactions
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety data below reflect the safety of BRINSUPRI in adult and pediatric patients aged 12 years and older with non-cystic fibrosis bronchiectasis (NCFB). A total of 1721 patients with NCFB were randomized in a double-blind, placebo-controlled clinical trial of 52 weeks duration (ASPEN) . The safety of BRINSUPRI was based on data from 1719 adult and pediatric patients aged 12 years and older who received at least one dose of BRINSUPRI or placebo. A total of 1156 patients received at least one dose of BRINSUPRI 10 mg or 25 mg orally once daily.
Table 1 shows the adverse reactions occurring at an incidence of โฅ2% and higher in BRINSUPRI-treated patients compared to placebo in the safety population from ASPEN.
Adverse Reaction | Placebo(N=563)n (%) | BRINSUPRI10 mg QD(N=582)n (%) | BRINSUPRI25 mg QD(N=574)n (%)
Upper respiratory tract infectionUpper respiratory tract infection includes coronavirus infection, COVID-19, influenza, upper respiratory tract infection, viral infection, and viral upper respiratory tract infection. โฆ
About this medicine
BRINSUPRI (brensocatib) is a dipeptidyl peptidase 1 (DPP1) inhibitor.
The chemical name for the active ingredient brensocatib monohydrate is (2S)-N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide monohydrate with a chemical formula of C23H24N4O4 โ H2O which corresponds to a molecular weight of 438.48 g/mol. Its structural formula is:
Brensocatib monohydrate drug substance is a white to off-white solid powder. It is slightly soluble at pH 1.2, freely soluble at pH 4.5, and very slightly soluble at pH 6.8 of aqueous media. It is also soluble in acetonitrile and sparingly soluble in ethanol.
BRINSUPRI tablets are available for oral administration in strengths of 10 mg and 25 mg brensocatib with the following inactive ingredients: dibasic calcium phosphate dihydrate, glyceryl dibehenate, microcrystalline cellulose, silicon dioxide, and sodium starch glycolate. โฆ
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID b56986ae-e7db-421e-b622-a7f41e321f3d. Read the full official label on DailyMed.